Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2010.505675 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence and impact of other malignancies after immunochemotherapy by fludarabine, cyclophosphamide, and rituximab as frontline treatment for chronic lymphocytic leukemia: A single-center retrospective study.
Clin Hematol Int
January 2025
Service d'Hématologie Clinique et Thérapie Cellulaire Hôpital Saint-Antoine.
Individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have a high risk of developing other malignancies (OMs). The development of OMs may be associated with the advanced age of CLL/SLL patients, presence of a tumor-promoting microenvironment, immune alterations inherent to CLL/SLL, or chemotherapy. Importantly, the occurrence of OMs following frontline fludarabine, cyclophosphamide and rituximab (FCR) treatment is associated with a reduction in the overall survival (OS).
View Article and Find Full Text PDFIncidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience.
Int J Cancer
December 2024
Hematology Department, Theagenio Cancer Hospital, Thessaloniki, Greece.
Poly(ADP-ribose) polymerase inhibitors (PARPi) target the DNA repair pathways and have been established in epithelial ovarian cancer (EOC) as maintenance therapy inducing prolonged survival. However, recently published data showed that PARPi may increase the risk of therapy-related myeloid neoplasms (t-MN) including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Herein, we investigated the incidence, characteristics, and management of t-MN among EOC patients after exposure to PARPi in a Greek Cancer Center.
View Article and Find Full Text PDFImplications of Clonal Hematopoiesis in Hematological and Non-Hematological Disorders.
Cancers (Basel)
December 2024
Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Clonal hematopoiesis (CH) is associated with an increased risk of developing myeloid neoplasms (MNs) such as myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML). In general, CH comprises clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). It is an age-related phenomenon characterized by the presence of somatic mutations in hematopoietic stem cells (HSCs) and hematopoietic stem and progenitor cells (HSPCs) that acquire a fitness advantage under selection pressure.
View Article and Find Full Text PDFMyelodysplastic syndromes among atomic bomb survivors in Nagasaki: similarities to and differences from de novo and therapy-related cases.
J Radiat Res
December 2024
Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki 852-8523, Japan.
Epidemiological studies for atomic bomb (A-bomb) survivors clearly demonstrated that A-bomb radiation increased the risk of hematological neoplasms, such as acute and chronic leukemia, and myelodysplastic syndromes (MDS) among survivors. Several studies on MDS among survivors investigated its characteristics, and it seems that MDS among survivors has different features from those seen in de novo MDS and therapy-related MDS. In this short review, we describe the differences of clinical features, chromosomal alterations and genome aberrations among them.
View Article and Find Full Text PDFTransplant options and outcomes for TP53 myeloid disease.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Malignant Hematology and Cellular Therapy, H. Lee Moffitt Cancer Center, Pembroke Pines, FL.
TP53-mutated myeloid disease is a constellation of abnormalities seen in both de novo and therapy-related acute myeloid leukemia and myelodysplastic syndrome. Historically, this group of disorders has had a poor prognosis. Newer treatment combinations allow patients to be treated with less toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!